GPC Biotech AG Presents New Satraplatin Preclinical Data At AACR-NCI-EORTC Meeting

MARTINSRIED/MUNICH, GERMANY -- (MARKET WIRE) -- 11/16/2005 -- -- Synergistic effect in vivo when satraplatin is combined with Taxol® (paclitaxel) in non-small cell lung cancer model -- Synergistic effect in vitro when satraplatin active metabolite is administered sequentially with various anticancer therapies, including Tarceva® (erlotinib) U.S. Research and Development Facilities in Waltham/Boston, Mass. and Princeton, N.J.-- GPC Biotech AG (Frankfurt: GPC) (TecDAX index) (NASDAQ: GPCB) today announced the presentation of new preclinical data on its lead drug candidate satraplatin at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications in Philadelphia, Pennsylvania. The meeting provides a forum for discussion of the latest findings and new directions in research in drug development, cancer therapeutics, and molecular targets.